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In 2015, we undertook a review of the existing paediatric subcutaneous insulin-prescribing sheet introduced to Cork 
University Hospital in 2013. This involved a retrospective analysis of 15 consecutive in-patient insulin prescribing 
charts and a questionnaire distributed to health professionals. Following this a new insulin prescribing chart was 
designed and implemented in 2016 and a re-audit was performed in 2017. 
 
Results 
The 2017 re-audit demonstrated that the new insulin chart was viewed as easier (95% of previous users n=18) and 
safer (n=16) to use. There was less confusion (2017: 28%, n=11/39 vs 2015: 50%, n=17/34 2015) and the ALERT system 
helped staff standardise hypo/hyperglycaemia management (71%, n=28). 
 
Conclusion 
The new paediatric insulin prescribing chart has improved safety and ease of prescribing insulin. The colour coded 







Type 1 Diabetes Mellitus (T1DM) is a common condition seen with a relatively high national incidence in the paediatric 
population in Ireland- 28.8 cases/100,000/year1. Intensive insulin therapy has been shown to achieve optimum 
glycaemic control and reduce the risk of future complications 2-4. Due to its narrow therapeutic index insulin has been 
identified as one of the top ten high-risk medicines worldwide5. Inadvertent over dosing can result in severe 
hypoglycaemia, which adds to morbidity associated with T1DM6-8. Insulin is one of the ten classes of drugs most 
frequently reported to be associated with medication related issues9. It has also consistently appeared in the top five 
drugs associated with medication errors in the US Pharmacopeia (USP) medication error-reporting scheme 
MEDMARX10. 
 
The National Diabetes Inpatient Audit UK, 2015, described insulin related prescription errors in 22% of inpatients with 
diabetes11. A study undertaken in an acute Irish teaching hospital found that of the 8 medication classes, which 
accounted for 75.8% of medication errors that caused harm from 2005-2009, two classes caused significantly more 
harm: insulin and opiates12. Between 2003-2009 six deaths and twelve incidents resulting in severe harm were 
reported to the National Reporting and Learning System in the UK13. Furthermore, incorrect or inappropriate insulin 
prescribing leads to suboptimal glycaemic control. Smith et al., found that hyperglycemia and hypoglycemia in medical 
and surgical inpatients were mostly related to inadequate prescribing, monitoring, and communication practices14. 
 
In order to eliminate these largely preventable errors, in 2010 the Irish Medicines Safety Network (IMSN) issued a 
document titled ‘Best Practice Guidelines for the Safe Use of Insulin in Irish Hospitals’15. This suggests a number of 
methods to reduce errors which were subsequently introduced into our department such as the development of an 
education programme on the practical aspects of insulin prescribing and administration and that hospitals should 
consider designing a drug chart solely for insulin prescribing and administration15. Nursing staff receive training 
regularly throughout the year by the diabetes nurse specialists while the NCHDs receive training every 6 months by a 
consultant paediatric endocrinologist and the paediatric diabetes nurse specialists. 
 
A number of centers worldwide have explored the benefits of a dedicated insulin-prescribing chart for the purpose of 
improving glycaemic control and reducing prescribing errors13-16. Queensland public hospitals in Australia introduced 
a standardised statewide insulin prescribing record: one for intravenous and one for subcutaneous insulin 
prescriptions which resulted in an improvement in insulin prescribing, documentation of administration and blood 
glucose management16. A Canadian tertiary-care teaching hospital found that the implementation of a standardised, 
preprinted insulin order set facilitated best practices for insulin therapy, improved patient safety and was highly 
supported by treating practitioners17. A further study in New South Wales found that introduction of an adult 
subcutaneous insulin-prescribing chart had positive impacts on glycaemic management for patients on subcutaneous 
insulin therapy during admission18.  
 
Methods 
At Cork University Hospital, a dedicated subcutaneous insulin-prescribing sheet was introduced within the 
Department in 2013 as a pilot project. The pilot period was completed within a year and the initial insulin prescribing 
chart was in regular use by January 2014 (Appendix 2). This included essential management information for example, 
capillary blood glucose (CBG) recording, carbohydrate intake at mealtimes, insulin:carbohydrate ratios and 
basal/bolus insulin prescriptions all on the one sheet. The initial Insulin:carbohydrate ratio (ICR) and insulin sensitivity 
factor (ISF) is calculated by the consultant paediatric endocrinologist.  
 
In January 2015 a review was undertaken to establish the compliance with and effectiveness of the existing insulin-
prescribing chart as had been in regular use since January 2014 (Appendix 2). This study had two parts (1.) A 
retrospective analysis of 15 paediatric inpatient subcutaneous insulin prescribing sheets chosen from 15 sequential 
admissions of newly diagnosed patients from January-May 2015. and (2.) a questionnaire regarding the design and 
usability of the insulin-prescribing chart distributed to thirty-four healthcare professionals chosen randomly from a 
selection of relevant groups working within the Department of Paediatrics and Child Health (including paediatric 
nursing staff, clinical nurse managers, diabetes nurse specialists, general and sub-specialist Consultant Paediatricians 
and doctors in training) during this time period. The objective was to use the data gathered from users and patient 
records to design an improved version of the insulin-prescribing sheet (Figures 1a-1b) in line with recommended 




    




       Figure 1b: Inner pages of new specific insulin prescribing chart including quasi graph 
 
 
The number of entries varied for each variable e.g. the patients allergy and weight were only entered on the insulin 
prescribing sheet once so N=15 for these variables. However, there were 270 insulin doses prescribed and 
subsequently administered within these 15 insulin prescribing charts so the prescribers signature, MCRP and nursing 
checks N=270 (Table 1) 
  
       Table 1. Comparative results of the Insulin Chart reviews from the 2015 and 2017 audits 
 
Variable Audit 2015 Audit 2017 
The allergy box is completed (Obligatory) 67% (10/15) 60% (9/15) 
The patient weight is noted on the chart  87% (13/15) 93.3% (14/15) 
Patient details are stated on the chart (Obligatory) 100% (15/15) 100% (15/15) 
The word ‘units’ has not been omitted when writing insulin 
dose 
77% (215/280)     1% (4/300) 
Insulin has been prescribed in the main kardex - 26.6% (4/15) 
The box been ticked to state insulin is prescribed in the main 
kardex 
- 6.6% (1/15) 
The insulin device is noted (Obligatory) - 2.66% (8/300) 
The Insulin type/name is documented (Obligatory) - 99.6% (299/300) 
The prescriber’s signature is documented (Obligatory) 100% (270/270) 99.6% (299/300) 
The prescriber’s MCRN is documented (Obligatory) - 100% (300/300) 
The prescriber has noted their details in the appropriate space 
in the back of the chart 
- 6.66% (1/15) 
Nursing staff have signed for administration of insulin 
(Obligatory) 
97% (263/270) 97% (291/300) 
Nursing details have been documented in the back of the chart - 100% (15/15) 
The nursing ‘checked by’ box is ticked (Obligatory) 87% (234/270)  n/a 
The insulin correction factor is omitted or incorrect  - 93.3% (14/15) 
Insulin-carbohydrate ratios are omitted or incorrectly filled 79% (145/183) 73% (182/250) 
Ketones have been checked if CBG >14  64% (62/97) 68% (72/106) 
CBG has been rechecked post hypoglycemic episode - 77% (77/100) 
CBG recorded In correct bracket range (Obligatory) - 91.1% (517/560) 
Carbohydrates consumed per meal are documented - 85% (254/299) 
The date is documented (Obligatory) - 95.8% (69/72) 
The basal Insulin type is documented (Obligatory) 69% 90.2% (65/70) 
The short acting insulin dose is documented (Obligatory) - 81.2% 
The ‘Given by’ section is signed (Obligatory) 97% (263/270) 97% (291/300) 
The ‘checked by’ section is signed (Obligatory) 87% (234/270) 97% (291/300) 
The time/meal at which insulin is to be given is noted 
(Obligatory) 
- 98.3% (295/300) 
The insulin dose and type is recorded in appropriate section on 
inner sheet of prescribing chart (Obligatory) 
- 81.2% (191/235) 
 
Note: - means that the variable was not recorded in the original 2015 audit cycle 
Obligatory means that the variable must be recorded for the insulin to be administered on the ward 
Our definition of the insulin-carbohydrate ratio having been omitted is that the ratio was omitted for that dose e.g. a lunchtime 
dose ratio of 1:5 was omitted but the nursing staff were still able to administer the insulin by basing it off the lunchtime dose 
administered the previous day. Our definition of an incorrectly filled insulin: carbohydrate ratio is if an insulin dose was 
administered based off of the previous day’s regimen as the current day’s prescription was incorrectly documented e.g. an 
individual number 1 or 5 without the second digit to complete the ratio. 
‘The short acting insulin dose is documented’ refers to the number of times the short acting insulin dose was documented relative 
to the number of times it was given.  
 
 
The results of the initial audit cycle were used to redesign the insulin prescribing chart which came into use in 2016. 
A repeat of the audit cycle was carried out in 2017 with a second retrospective analysis of 15 consecutive in-patient 




Of note, no serious adverse events related to insulin prescribing had been recorded since introduction of the first 
insulin-prescribing chart in 2013. 
Analysis of the former insulin-prescribing chart demonstrated issues with proper completion and documentation 
(Table 1). 79% of the insulin: carbohydrate ratios were left blank and in 76% of entries, the word units were either not 
documented or documented as ‘iu’ or ‘u.’  
Analysis of questionnaires identified issues with the design and usability of the former insulin-prescribing chart (Table 
2). While most respondents perceived this chart to be safer than previous, some design changes were suggested. The 
first usability problems are related to the information layout of the sheets in which it leads to confusion (50%) and 
there is a need for additional space for carbohydrate counting (38.3%). The 2013 chart blood glucose recording did 
not clearly illustrate abnormal blood glucose levels (47.1%). Inclusion of an action system outlining guidelines for 
treatment of hypo and hyperglycemia and more columns for recording of CBG levels and the prescribing of insulin 
corrections were suggested. Using a graph to portray CBG readings was also suggested, so readings that are out of 
range can be more readily identified.  
    Table 2: Comparison of results from staff questionnaires 
 
Note:  82% of  Staff members did not participate in 2015 Audit  
 Audit 2015 Audit 2017 
Adequate writing space is provided  61.7% 61.5% 
It is clearly visible when CBG levels are out of normal range 52.9% 87% 
There is a need to provide additional dose calculation space 64.7% 53.8% 
The prescribing chart is user friendly 82.3% 82% 
Confusion arose when completing the chart 50% 28% 
It is easy to understand the basic functionality of chart 97% 94.8% 
The prescribing chart is self explanatory - 46% 
There was adequate training or information on how to use the 
insulin prescribing sheet 
88.2% 28.2% 
It is easier to appreciate CBG trends due to the colour coded quasi 
graph 
- 89.7% 
CBG levels are referred to when prescribing (Doctors) or 
administering (Nursing staff) insulin 
88.2% 87% 
The use of the pre-printed ‘units’ reduces use the writing of words 
‘units’ or abbreviated ‘iu’ 
- 87% 
The ALERT system is useful to standardise hypo/hyper glycaemia 
treatment 
- 71% 
The non-administration of insulin codes (Reasons for non-
administration of the prescribed insulin dose) should be included 
in the prescribing chart 
94.1% 53.8% 
The font used in the insulin prescribing chart is appropriate 88.2% 89.7% 
 
Following approval by the Quality Office of Cork University Hospital, the new insulin-prescribing record for the 
administration of subcutaneous insulin to paediatric patients was launched in December 2016 and is now used in 
regular clinical practice within the Department.   
 
Analysis of the new insulin prescribing chart in 2017 demonstrated an improvement in prescribing and documentation 
(Table 1). A significant issue identified was that the short acting insulin dose was only documented 81.2% of the time 
relative to the number of times it was given. The main reasons for such events were failure to prescribe the morning 
dose the night before with the on call staff unable to come while managing other patients. Similar events occurred at 
busy peak times for patient care e.g. weekend doses. A diabetes nurse specialist at our center has gained certification 
as a nurse prescriber to prevent such events going forwards. Similarly, analysis of questionnaires completed by 39 
health care professionals demonstrated many improvements (Table 2). It was now more clearly visible when CBG 
levels are out of range (87% 2017 vs 52.9% 2015) and there was less confusion when completing the chart (28% 2017 
vs 50% 2015). The introduction of the colour coded Quasi graph made it easier to appreciate CBG trends (89.7%). The 
ALERT system helped NCHDs and nurses standardize hypo/hyperglycaemia treatment (71%). Table 3 shows the current 
insulin sheet was safer and easier to use than the previous itineration with the majority of staff satisfied with its use 
and design overall. 
 
Table 3: Overall Quality of Insulin Sheet: Table 3 shows the current insulin sheet was safer and easier to use than the 
previous itineration with the majority of staff satisfied with its use and design overall. 
 
Overall Quality of the Insulin Sheet:     
Is administering and recording the subcutaneous 
insulin order easier with the current subcutaneous 












Have there been any unintended consequences 
from using the prescribing sheet that you 
personally are aware of? e.g. missed doses of 










Please rate the safety of the new insulin 













Please rate your level of satisfaction with the 















Is there a clear communication between 











Would you make any design changes based on 











Implementation of insulin to carbohydrate 
counting leads to more accurate dosing of insulin 














Our findings demonstrated the need for an updated insulin-prescribing chart within the Department following the 
introduction of the initial dedicated insulin prescribing chart in 2013. Prior to 2013, all insulin prescriptions were 
prescribed in the main drug Kardex akin to prescribing analgesia or an antibiotic. The IMSN suggest that an insulin 
prescribing chart should incorporate the following safety features: the word ‘units’ pre-printed wherever a dose of 
insulin has to be prescribed to avoid the use of abbreviated ‘u’ or ‘iu’. Using U as an abbreviation for units can lead to 
10 times overdosing as if U is mistaken as 0 and IU can lead to I being mistaken for 1 e.g. when 6IU is prescribed, 
61units could be given instead of 6. A reference list of the insulin most commonly prescribed in hospitals, classified by 
the different formulations of insulin and the provision of space for double signatures on the drug chart to prompt staff 
to seek a second person to check insulin doses prior to administration.  
The Australian Commission on Safety and Quality in Healthcare analysed a number of insulin prescribing charts and 
offered numerous potential design solutions including the use of a quasi-graph design as a method for recording CBG 
levels (Figure 1b.) as it gave a visual representation of the trend in CBG readings while also allowing numerical values 
to be recorded and the use of a colour coded track and trigger system for the detection of abnormal CBG levels19. 
 
The newly designed Paediatric Subcutaneous Insulin Prescribing and Capillary Blood Glucose Record (Figures 1a-1b), 
has a number of additional features. (1.) The front cover includes a check box tool to ensure insulin has also been 
prescribed on the main drug kardex. (2.) The word ‘units’ has been clearly printed in each prescribing space, reducing 
the risk that the prescriber will include an abbreviated ‘u’ or ‘iu’ instead. (3.) Each chart has space for recording five 
days of information, with each day clearly separated (4.) Recording of CBG is done on a colour-coded quasi-graph, 
which gives a visual picture of the variation of CBG levels throughout the day and will clearly demonstrate if recorded 
CBG levels are within target range. (5.) As recommended by staff, additional spaces for CBG recording have been 
included, along with prompts to ensure a two-hour post prandial CBG is checked after every meal. (6.) The most 
commonly used long and short acting insulin have been listed and should be circled by the prescriber in addition to 
writing the insulin prescription in the spaces provided at the front and back of the chart. (7.) A colour coded alert 
system, with a corresponding action plan has also been included in the new insulin-prescribing chart. (8.) Often doctors 
in training are called to prescribe insulin or review CBG levels that are out of range. Those with limited experience in 
the management of diabetes may be unsure of how to manage abnormal CBG levels. For this reason, a management 
plan for hypoglycaemia and hyperglyceaemia has been included. This ensures a standardized approach to the 
management of diabetes in all inpatients, which should result in better glycaemic control and consistency in the 
patient education process20.  
 
This insulin-prescribing chart is a step towards eliminating preventable errors associated with the prescribing and 
administration of insulin. Due to the frequency of medication errors and potentially fatal consequences of the 
administration of incorrect insulin doses, it is vital that we have safe and effective prescribing and administration 
records. 
 
The biggest barrier to safe insulin prescribing from the 2017 re-audit is the persistence in confusion (28%) in 
completing the chart as only 28% of staff felt that they had received adequate training with using the insulin 
prescribing chart. This reflects a lack of training so a first step is to provide dedicated staff education sessions on the 
insulin prescribing chart.  
 
Limitations to the above study include the small sample sizes and that some respondents who responded to the 
questionnaire in 2017 had not used the previous 2015 insulin prescribing sheet- mainly new NCHDs who invariably 
rotate through sites.   
 
Achieving the safest, most effective insulin chart will be a dynamic process. Therefore, further audits of this chart will 
be required to again evaluate compliance and usability and make the necessary improvements ideally to further 
eliminate preventable insulin prescribing errors. This will involve further redesigning of the insulin prescribing chart 
and further staff education sessions. Ultimately we aim to produce a paediatric diabetes insulin prescribing sheet to 
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